Humanin: The Peptide Encoded in Mitochondrial DNA

Humanin is a peptide with an unusual origin. It is encoded not in the nuclear genome but within mitochondrial DNA, in a region of the 16S ribosomal RNA gene. It was the first identified member of a class now called mitochondrial-derived peptides, and its discovery changed how mitochondria are understood.

This guide situates Humanin within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

Where humanin came from

Humanin was identified in surviving neurons from the brain of a patient with Alzheimer's disease — researchers looking for factors protecting cells that had not died found a peptide conferring resistance to neuronal death.

The surprise was its origin. Mitochondrial DNA was understood to encode a small set of components for the respiratory chain and the mitochondrion's own translational machinery. Humanin is encoded within the 16S rRNA gene region of mtDNA and functions as a signalling molecule acting outside the mitochondrion.

This established that mitochondria participate in retrograde signalling — communicating their functional state outward to the rest of the cell and beyond, rather than simply producing energy on instruction. Other mitochondrial-derived peptides have since been described, including MOTS-c and the SHLP family.

What humanin does

Humanin's best-characterized activity is cytoprotection. It inhibits apoptosis, particularly through interaction with pro-apoptotic Bcl-2 family proteins such as Bax, preventing the mitochondrial events that commit a cell to death.

It binds cell surface receptors including a complex involving the ciliary neurotrophic factor receptor and gp130, and interacts with IGF binding protein 3 — connecting it to the IGF-1 axis, which is itself central to longevity biology across species.

Reported effects in experimental systems include protection against oxidative stress, improvements in insulin sensitivity, and reduced neuronal death in models of neurodegeneration. A more potent analog, HNG, is commonly used in research because native humanin is relatively short-lived.

The longevity association

Circulating humanin levels decline with age in humans. More interestingly, observational work has reported higher humanin levels in the offspring of centenarians compared with age-matched controls — a population enriched for genetic factors favoring exceptional longevity.

Similar patterns have been described in long-lived animal models, including species and strains with extended lifespan.

The interpretive caution is essential and frequently omitted. These are observational associations. Higher humanin in long-lived individuals is consistent with humanin contributing to longevity, and equally consistent with it being a marker of better mitochondrial function that has other causes. Association does not establish that raising humanin extends life.

There are no human clinical trials demonstrating that administering humanin or its analogs produces clinical benefit or affects aging.

Status

Humanin is not FDA-approved, is not an established compounding substance, and has no established human therapeutic use. Material sold under this name is unregulated.

Its genuine value at present is conceptual. Mitochondrial-derived peptides represent a real and relatively recent addition to the understanding of how cellular energy status is communicated, and that framework is likely to matter clinically in time.

For patients interested in mitochondrial health today, the interventions with actual evidence — exercise, which is the most potent known stimulus to mitochondrial biogenesis, sleep, and management of metabolic disease — remain the substantive answer.